EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD

Tom Ryu, Yeon Joo Seo, Jaejun Lee iD, Ji Won Han iD, Hyun Yang iD, Keungmo Yang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tom Ryu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, College of Medicine, Soonchunhyang University, Seoul 044…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Cardiovascular Diseases, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Soonchunhyang University Research Fund, the Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renin–angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), have been associated with improved outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to assess the differential impact of ACEIs versus ARBs on survival and cardiovascular outcomes in individuals with MASLD. Using data from the UK Biobank, we identified 52,143 participants with exclusive use of either an ACEI or ARB. Individuals with viral, autoimmune, cholestatic, or alcohol-related liver disease were excluded. MASLD was defined as fatty liver index ≥ 60 with ≥1 cardiometabolic risk factor. Inverse probability of treatment weighting (IPTW) was used to adjust for confounders. Outcomes included all-cause mortality, cardiovascular events, hepatic decompensation, and hepatocellular carcinoma (HCC), analyzed using Cox proportional hazards models. Among MASLD participants, ARB use was associated with significantly lower all-cause mortality compared to ACEI use (HR, 0.94; 95% CI, 0.90–1.00; p = 0.031) after IPTW adjustment. Cardiovascular risk was also lower with ARBs (HR, 0.92; 95% CI, 0.89–0.96; p < 0.001), particularly in subgroups with BMI ≥ 25 kg/m2, no diabetes, and advanced fibrosis. No differences in hepatic decompensation or HCC incidence were observed. Benefits of ARBs were not significant in participants without steatotic liver disease. ARB use was associated with improved survival and reduced cardiovascular events in individuals with MASLD, whereas ACEIs expressed no comparable benefit. These findings suggest that ARBs might be a more effective RAS inhibitor subclass in MASLD and support their preferential use in patients with steatotic liver disease requiring antihypertensive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardiovascular DiseasesFatty LiverHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

angiotensin II receptor blockersangiotensin converting enzyme inhibitorscardiovascular eventmetabolic dysfunction-associated steatotic liver diseasesurvival

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, College of Medicine, Soonchunhyang University, Seoul 04401, Republic of Korea.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

ORCID-Profile: Jaejun Lee, Ji Won Han, Hyun Yang

Förderung

  • National Research Foundation of Korea
  • Soonchunhyang University Research Fund
  • the Korea Health Industry Development Institute
  • the Ministry of Health & Welfare, Republic of Korea
  • the Soonchunhyang University Research Fund

Zitieren

APA

Ryu, T., Seo, Y. J., Lee, J., Han, J. W., Yang, H., & Yang, K. (2025). Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010061

Vancouver

Ryu T, Seo YJ, Lee J, Han JW, Yang H, Yang K. Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010061

BibTeX
@article{Ryu2025,
  author = {Ryu, Tom and Seo, Yeon Joo and Lee, Jaejun and Han, Ji Won and Yang, Hyun and Yang, Keungmo},
  title = {Class-Specific Effects of ARBs Versus ACE Inhibitors on Survival and Cardiovascular Outcomes in MASLD},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010061}
}
Kostenlos starten →